Home Tags Tubulin-targeting agent

Tag: tubulin-targeting agent

FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...

Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer

The Phase 3 SOROYA trial demonstrated  promising response rates with mirvetuximab soravtansine, previously known as  IMGN853, in patients with platinum-resistant ovarian cancer and high folate receptor–alpha...